These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37385888)

  • 41. The current status of COVID-19 vaccines. A scoping review.
    Rueda-Fernández M; Melguizo-Rodríguez L; Costela-Ruiz VJ; González-Acedo A; Ramos-Torrecillas J; Illescas-Montes R
    Drug Discov Today; 2022 Nov; 27(11):103336. PubMed ID: 35995361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Humoral and cellular immune memory to four COVID-19 vaccines.
    Zhang Z; Mateus J; Coelho CH; Dan JM; Moderbacher CR; Gálvez RI; Cortes FH; Grifoni A; Tarke A; Chang J; Escarrega EA; Kim C; Goodwin B; Bloom NI; Frazier A; Weiskopf D; Sette A; Crotty S
    Cell; 2022 Jul; 185(14):2434-2451.e17. PubMed ID: 35764089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
    Marchevsky NG; Li G; Aley P; Costa Clemens SA; Barrett JR; Belij-Rammerstorfer S; Bibi S; Clutterbuck E; Dold C; Felle S; Flaxman A; Folegatti P; Jenkin D; Gilbert S; Kelly S; Lambe T; Plested E; Ramasamy M; Singh N; Smith H; Taylor S; Weckx L; Pollard AJ; Voysey M;
    EBioMedicine; 2022 Jul; 81():104128. PubMed ID: 35779491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
    Madhi SA; Baillie V; Cutland CL; Voysey M; Koen AL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Kwatra G; Ahmed K; Aley P; Bhikha S; Bhiman JN; Bhorat AE; du Plessis J; Esmail A; Groenewald M; Horne E; Hwa SH; Jose A; Lambe T; Laubscher M; Malahleha M; Masenya M; Masilela M; McKenzie S; Molapo K; Moultrie A; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Rossouw L; Taoushanis C; Tegally H; Thombrayil A; van Eck S; Wibmer CK; Durham NM; Kelly EJ; Villafana TL; Gilbert S; Pollard AJ; de Oliveira T; Moore PL; Sigal A; Izu A; ;
    N Engl J Med; 2021 May; 384(20):1885-1898. PubMed ID: 33725432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.
    Ssentongo P; Ssentongo AE; Voleti N; Groff D; Sun A; Ba DM; Nunez J; Parent LJ; Chinchilli VM; Paules CI
    BMC Infect Dis; 2022 May; 22(1):439. PubMed ID: 35525973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021.
    Makonokaya L; Kapanda L; Woelk GB; Chauma-Mwale A; Kalitera LU; Nkhoma H; Zimba S; Chamanga R; Golowa C; Machekano R; Maphosa T
    Int J Environ Res Public Health; 2023 Nov; 20(23):. PubMed ID: 38063553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
    Cohn BA; Cirillo PM; Murphy CC; Krigbaum NY; Wallace AW
    Science; 2022 Jan; 375(6578):331-336. PubMed ID: 34735261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
    Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove CA; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jeanes C; Kalra PA; Kyriakidou C; Bradley JM; Munthali C; Minassian AM; McGill F; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Fries L; Cho I; McKnight I; Glenn G; Rivers EJ; Robertson A; Alves K; Smith K; Toback S
    Clin Infect Dis; 2023 Feb; 76(3):398-407. PubMed ID: 36210481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2022 Jun; 84(6):795-813. PubMed ID: 35405168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
    Fong Y; McDermott AB; Benkeser D; Roels S; Stieh DJ; Vandebosch A; Le Gars M; Van Roey GA; Houchens CR; Martins K; Jayashankar L; Castellino F; Amoa-Awua O; Basappa M; Flach B; Lin BC; Moore C; Naisan M; Naqvi M; Narpala S; O'Connell S; Mueller A; Serebryannyy L; Castro M; Wang J; Petropoulos CJ; Luedtke A; Hyrien O; Lu Y; Yu C; Borate B; van der Laan LWP; Hejazi NS; Kenny A; Carone M; Wolfe DN; Sadoff J; Gray GE; Grinsztejn B; Goepfert PA; Little SJ; Paiva de Sousa L; Maboa R; Randhawa AK; Andrasik MP; Hendriks J; Truyers C; Struyf F; Schuitemaker H; Douoguih M; Kublin JG; Corey L; Neuzil KM; Carpp LN; Follmann D; Gilbert PB; Koup RA; Donis RO; ; ;
    Nat Microbiol; 2022 Dec; 7(12):1996-2010. PubMed ID: 36357712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Fu Y; Wu K; Wang Z; Yang H; Chen Y; Wu L; Yanagihara R; Hedges JR; Wang H; Deng Y;
    Vaccine; 2023 Oct; 41(42):6339-6349. PubMed ID: 37741761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
    van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
    J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low clinical utility of testing for anti-platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoV-19 vaccine.
    Barefah AS; Radhwi OO; Alamri SS; Alahwal HM; Denetiu I; Almohammadi AT; Bahashwan SM; Qari MH; Algaissi A; Alamer E; Alhazmi A; Abuzenadah AM; Nasraldeen WH; Alzahrani SH; Hashem AM
    Int J Lab Hematol; 2022 Apr; 44(2):424-429. PubMed ID: 34850575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.